The major clinically concluded CANTOS study tested the therapeutic effect of the anti-IL-1β antibody, Canakinumab, in a group of patients after myocardial infarction, and showed 31% reduction in cardiovascular and all-cause mortality in certain, but not all, groups of patients (11). This evidence concerns the gene IL1B and myocardial infarction.